Candesartan Cilexetil 32mg

DRUG2 trials

Sponsors

AstraZeneca, Pharmtechnology LLC

Conditions

BioequivalenceNon-diabetic Nephropathy With Hypertension

Phase 1

The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions

CompletedNCT04012307

Pharmtechnology LLCBioequivalence

Start: 2019-07-11End: 2019-08-14Updated: 2019-11-18

Phase 4

ARIA (Atacand Renoprotection In NephropAthy Pt.)

CompletedNCT00573430

AstraZenecaNon-diabetic Nephropathy With Hypertension

Start: 2007-12-31End: 2009-08-31Updated: 2011-08-23